ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2728

Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients

Pelin Ünsal1, Pamir Cerci2, Şükrü Alper Açıkgöz2, Göksal Keskin2 and Ümit Ölmez2, 1Ankara University School of Medicine, Ankara, Turkey, 2Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Behcet's syndrome, interleukins (IL), pathogenesis and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Vasculitis Poster III: Other Vasculitis Syndromes

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Behcet’s disease (BD) is a systemic vasculitis disorder of unknown etiology with recurrent exacerbations and remissions. The etiopathogenesis of the disease is still unclear. The most investigated cytokine in the pathogenesis of the disease is interleukin (IL) -1 family. A new member of the IL-1 cytokine family, IL-36Ra (Receptor Antagonist), stimulates dendritic cells from the host cells of innate and acquired immunity. In this study we investigated whether the level of serum IL-36Ra increase or not in the etiopathogenesis of Behcet’s disease, its effect on disease activity and clinical findings.

Methods:

Serum IL-36Ra levels were measured by (ELISA) kits following the manufacturer’s instructions. All BD patients recruited for this study met the 1990 international criteria for classification of BD.

Results:

31 of the patients were active disease (51.7%). Demographic and clinical parameters are shown in Table 1.

Table 1: Demographic and clinical characteristics of Behcet’s patients and healthy controls

Parameter All BD Patients (n:60) Active BD Patients (n:31)

Healthy Controls (n:20)

Age (year) 41 ± 11,1 (mean+SD) 38,4 ± 11,3 40,2 ± 13
Sex (M/F) 29/31 14/17 10/10
Oral ulcers 59 (98.3%) 25 (80.6%) –
Genital ulcers 48 (80%) 23 (74.2%) –
Thrombophlebitis 14 (23.3%) 7 (22.6%) –
Arthritis 22 (36.6%) 11 (35.5%) –
Uveitis 30 (50%) 11 (35.5%) –
Deep vein thrombosis 18 (30%) 6 (19.4%) –
CNS involvement 5 (8.3%) 4 (12.9%) –

Serum IL-36Ra levels were found to be 15.36 ± 13.26 pg / ml in the patient group and 17.90 ± 13.03 pg / ml in the control group (p = 0.677). Serum IL-36Ra levels were found to be 17.80 ± 10.63 pg / ml in the active patient group and serum IL-36 Ra level in the inactive patient group was found to be 12.77 ± 7.12 pg / ml. A statistically significant difference was found between IL-36Ra levels in active and inactive patient groups (p = 0.037). There was no statistically significant difference between IL-36Ra levels (p = 0.636 and p = 0.207, respectively) between active patient and inactive patient group and control group. Serum IL-36Ra levels were significantly higher in patients with Behçet’s disease than those without oral ulcers (p = 0.018). In addition, serum IL-36Ra levels (24.45 ± 11.58 pg / ml) were higher in patients with neurological involvement than those without neurological involvement (14.45 ± 8.71 pg / ml) (p = 0.011). No statistically significant difference was found between serum IL-36Ra and other systemic manifestations.

Conclusion:

According to our results, there was a statistically significant difference between IL-36Ra and oral ulcers, neurological involvement, disease activity and CRP. More study is needed to determine the role of IL-36Ra in the pathogenesis of Behcet’s disease.


Disclosure: P. Ünsal, None; P. Cerci, None; Ş. A. Açıkgöz, None; G. Keskin, None; Ü. Ölmez, None.

To cite this abstract in AMA style:

Ünsal P, Cerci P, Açıkgöz ŞA, Keskin G, Ölmez Ü. Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/serum-levels-of-interleukin-36-receptor-antagonist-in-behcets-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-levels-of-interleukin-36-receptor-antagonist-in-behcets-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology